Cancer Genetics and Implications for Clinical Management

Nigel B Jamieson; David K Chang; Andrew V Biankin

doi:10.1016/j.suc.2015.05.003

Cancer Genetics and Implications for Clinical Management

Surg Clin North Am. 2015 Oct;95(5):919-34. doi: 10.1016/j.suc.2015.05.003. Epub 2015 Jun 23.

Authors

Nigel B Jamieson¹, David K Chang², Andrew V Biankin³

Affiliations

¹ Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK; Academic Unit of Surgery, School of Medicine, College of Medical, Veterinary and Life Sciences, Glasgow Royal Infirmary, University of Glasgow, Alexandra Parade, Glasgow G31 2ER, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Alexandra Parade, Glasgow G31 2ER, UK.
² Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, New South Wales 2010, Australia; Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia; Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, New South Wales 2200, Australia; Faculty of Medicine, South Western Sydney Clinical School, University of NSW, Goulburn St, Liverpool, New South Wales 2170, Australia.
³ Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, New South Wales 2010, Australia; Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia; Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney, New South Wales 2200, Australia; Faculty of Medicine, South Western Sydney Clinical School, University of NSW, Goulburn St, Liverpool, New South Wales 2170, Australia. Electronic address: andrew.biankin@glasgow.ac.uk.

PMID: 26315514
DOI: 10.1016/j.suc.2015.05.003

Abstract

There is now compelling evidence that the molecular heterogeneity of cancer is associated with disparate phenotypes with variable outcomes and therapeutic responsiveness to therapy in histologically indistinguishable cancers. This diversity may explain why conventional clinical trial designs have mostly failed to show efficacy when patients are enrolled in an unselected fashion. Knowledge of the molecular phenotype has the potential to improve therapeutic selection and hence the early delivery of the optimal therapeutic regimen. Resolution of the challenges associated with a more stratified approach to health care will ensure more precise diagnostics and enhance therapeutic selection, which will improve overall outcomes.

Keywords: Genomics; Next-generation sequencing; Pancreatic cancer; Stratified medicine; Translational medicine.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Drug Resistance, Neoplasm / genetics
Genomics*
Genotype
Humans
Mutation
Neoplasms / drug therapy*
Neoplasms / genetics
Phenotype
Precision Medicine / methods*

Substances

Antineoplastic Agents
Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding